Literature DB >> 7028866

Monoclonal antibodies recognizing normal human T lymphocytes and malignant human B lymphocytes: a comparative study.

P J Martin, J A Hansen, A W Siadak, R C Nowinski.   

Abstract

We have undertaken a direct comparison of 8 different murine monoclonal antibodies that recognize antigens shared by human T cells and certain malignant B cells. Immune precipitation, lysostripping, and competitive binding experiments indicate that the antigenic determinants detected by antibodies Leu 1, T101, 17F12, SC1, A50, OKT1, and 10.2 are closely associated on the same molecular species and may in fact be identical. The antigenic determinant recognized by antibody 12.1, which has properties similar to the 1 detected by other antibodies, is present on a distinct cell-surface molecule. Our results emphasize the importance of a quantitative direct comparison of different monoclonal antibodies in distinguishing newly reported antibodies from those already described. Such a comparison can resolve apparent discrepancies that arise either from methodologic variations or from differences in antibody avidity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028866

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Tonsillar mapping of determinants found on normal lymphoreticular (T,B,K, immature and macrophage) and myeloblastic leukemia cells.

Authors:  E M McMillan; L Stoneking; G B Humphrey; J Rapacz
Journal:  Am J Pathol       Date:  1987-03       Impact factor: 4.307

2.  Distinct patterns of transmembrane calcium flux and intracellular calcium mobilization after differentiation antigen cluster 2 (E rosette receptor) or 3 (T3) stimulation of human lymphocytes.

Authors:  C H June; J A Ledbetter; P S Rabinovitch; P J Martin; P G Beatty; J A Hansen
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

3.  In situ identification of immune competent cells in gastrointestinal mucosa: an evaluation by immunoelectronmicroscopy.

Authors:  M Vecchi; E Berti; M Primignani; M Monti; D Agape; G Torgano; E Arosio; R de Franchis
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

4.  Expression of human CD antigens, including CD1 and CD25, by human x mouse interlineage leukaemia hybrids.

Authors:  G M Taylor; H Morten; T Carr; C Harrison; J Ridway; P Morris Jones
Journal:  Immunology       Date:  1987-12       Impact factor: 7.397

5.  The development of gut associated lymphoid tissue in the terminal ileum of fetal human intestine.

Authors:  J Spencer; T T MacDonald; T Finn; P G Isaacson
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

6.  Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques.

Authors:  W S Selby; G Janossy; M Bofill; D P Jewell
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

7.  Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by a monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes.

Authors:  J Spencer; N Cerf-Bensussan; A Jarry; N Brousse; D Guy-Grand; A S Krajewski; P G Isaacson
Journal:  Am J Pathol       Date:  1988-07       Impact factor: 4.307

8.  Routine flow cytometric diagnosis of lymphoproliferative disorders.

Authors:  I G Barr; B H Toh
Journal:  J Clin Immunol       Date:  1983-04       Impact factor: 8.317

9.  Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern.

Authors:  H M Lokhorst; S E Boom; B J Bast; P J Peters; T F Tedder; J Gerdes; E Petersen; R E Ballieux
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

10.  Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse.

Authors:  S H Swerdlow; J A Habeshaw; L J Murray; H S Dhaliwal; T A Lister; A G Stansfeld
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.